Beijing Huafang Investment

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

Tangshi Technology is a platform for research and development for carbon-based materials. It helps in creation, and use of conductive agents and negative electrode materials.

FineImmu produces cell therapy drugs and immunodiagnostic products. The drug predicts the anti-tumor immune function of PD-1 and PD-L1 and the therapeutic effect of immune checkpoint inhibitors such as CTLA4. The company's contact modes are by phone and physical address.